Advisory boutique · United States

Tungsten Advisors

Deals
4
Latest
Aug 2026
Compare

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deal size
Custom range

4 of 4 deals

Deals Tungsten Advisors advised on, most recent first
Advisers
Aug 2026 Cy Biopharma –Ensysce BiosciencesAcquisitionFinancial adviser to Ensysce Biosciences (acquirer)Completed–Biotech+1 Troutman Pepper Locke (buy-side)Orrick (sell-side)Wedbush Securities (sell-side)H.C. Wainwright & Co. Ensysce Biosciences acquisition of Cy Biopharma
Jul 2026 Vidya Therapeutics –Processa PharmaceuticalsAcquisitionFinancial adviser and fairness opinion to Processa Pharmaceuticals (acquirer)Completed–Biotech+1 Leerink Partners (sell-side)Cooley (sell-side)Katten Muchin Rosenman (buy-side) Processa Pharmaceuticals acquisition of Vidya Therapeutics
Jul 2026 Avere Therapeutics –NextCureMergerFinancial adviser to NextCure (acquirer)Announced–Biotech+1 Sullivan & CromwellSidley AustinGibson Dunn (sell-side)Wedbush Securities (sell-side) NextCure and Avere Therapeutics merger
Mar 2026 Unleash-owned rights to UIO-524, UIO-525 and UIO-526 Unleash Immuno OncolyticsTransCode TherapeuticsAsset saleFinancial adviserPending–Biotech+2 TransCode Therapeutics acquisition of Unleash-owned rights to UIO-524, UIO-525 and UIO-526

Activity

Deals by year
Tungsten Advisors: deals by year2025: 0, 2026 YTD: 40123420252026 YTD: 4 M&A42026 YTDM&AEquity raisings

By announcement date; raisings and IPOs by their own date.

Deals by sector
Tungsten Advisors: deals by sectorBiotech4

Sector of the business bought or funded.

Deals by size
Tungsten Advisors: deals by sizeUndisclosed4

Disclosed value in US dollars.

Most often across the table

Firms advising the other side of the same deals.

Offices and contact

Contact

From the firm's own website.

Suggest a correction

A missing deal, a wrong role or an office to add. A link to a public source helps.